HomeInsightsStock Comparison

Alpa Laboratories Ltd vs Syncom Formulations India Ltd Stock Comparison

Alpa Laboratories Ltd vs Syncom Formulations India Ltd Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

  • The Latest Trading Price of Alpa Laboratories Ltd is ₹ 65.01 as of 30 Apr 15:30 . The P/E Ratio of Alpa Laboratories Ltd changed from 10.4 on March 2022 to 10.5 on March 2021 . This represents a CAGR of 0.19% over 5 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Alpa Laboratories Ltd changed from ₹ 146.23 crore on March 2022 to ₹ 76.06 crore on March 2021 . This represents a CAGR of -12.25% over 5 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Alpa Laboratories Ltd for the Dec '25 is ₹ 29.96 crore as compare to the Sep '25 revenue of ₹ 29.32 crore. This represent the growth of 2.18% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Alpa Laboratories Ltd for the Dec '25 is ₹ 2.42 crore as compare to the Sep '25 ebitda of ₹ 0.82 crore. This represent the growth of 195.12% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Alpa Laboratories Ltd changed from ₹ 5.1 crore to ₹ 1.9 crore over 7 quarters. This represents a CAGR of -43.12% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The Dividend Payout of Alpa Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Alpa Laboratories Ltd

  • M/s Alpa Laboratories, formed in 1967, was incorporated as Private Limited Company in the name of Alpa Laboratories Private Limited on March 18, 1988 for manufacture of pharmaceutical formulations.
  • In 1998, the Company was converted into a Public Limited Company with effect from September 3, 1998 with the name of 'Alpa Laboratories Limited'.
  • The facility has dedicated manufacturing areas for different Finished Dosage Forms (FDFs) including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels. In 1997, the company has initiated setting of a new manufacturing unit at Rau(Indore District), Madhya Pradesh.
  • The unit commenced commercial production in the year 1999 of all types of formulations viz.
  • Injectables (Vials/Ampoules both liquid and Dry), tablets, capsules, eye/ear drops, ointment and creams.

About Syncom Formulations (India) Ltd

  • Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
  • The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
  • Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
  • Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Alpa Laboratories Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Alpa Laboratories Ltd or Syncom Formulations (India) Ltd?

Market cap of Alpa Laboratories Ltd is 136 Cr while Market cap of Syncom Formulations (India) Ltd is 1,290 Cr

What are the key factors driving the stock performance of Alpa Laboratories Ltd and Syncom Formulations (India) Ltd?

The stock performance of Alpa Laboratories Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alpa Laboratories Ltd and Syncom Formulations (India) Ltd?

As of May 4, 2026, the Alpa Laboratories Ltd stock price is INR ₹65.01. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹13.73.

How do dividend payouts of Alpa Laboratories Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Alpa Laboratories Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions